Compare Nu Holdings Ltd (NU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs GeneDx Holdings Corp — how do they compare? Nu Holdings Ltd trades at $15.49 (market cap $75.26B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Nu Holdings Ltd is far larger — about 36.9× GeneDx Holdings Corp's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and GeneDx Holdings Corp for 19 Days on average.
| NU | WGS | |
|---|---|---|
Market Cap | $75.26B | $2.04B |
Volume | 82,363,718 | 659,215 |
Sector | Financials | Health |
52-Week High | $18.76 | $167.51 |
52-Week Low | $11.60 | $34.51 |
Typical Hold Time | 53 Days | 19 Days |
Enterprise Value | $97.88B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
